Intercept Pharmaceuticals, Inc. (ICPT)

Intercept Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Cash & Equivalents	103.66	55.86	92.83	65.65	74.78	43.25
Short-Term Investments	219.98	435.05	334.98	411.52	582.57	392.91
Cash & Cash Equivalents	323.63	490.91	427.81	477.17	657.35	436.16
Cash Growth	-34.99%	14.75%	-10.34%	-27.41%	50.71%	5.12%
Receivables	32.48	26.86	28.34	41.55	38.04	25.69
Inventory	2.65	6.46	7.88	9.03	8.46	7.11
Other Current Assets	24.68	15.89	43.99	18	17.46	13.46
Total Current Assets	383.45	540.13	508.02	545.74	721.32	482.43
Property, Plant & Equipment	0.82	0.99	3.28	6.33	5.2	10.41
Other Long-Term Assets	8.9	12.6	15.72	28.42	28.37	16.33
Total Long-Term Assets	9.72	13.58	19.01	34.75	33.57	26.74
Total Assets	393.16	553.71	527.02	580.49	754.89	509.17
Accounts Payable	89.49	116.98	103.78	171.04	153.97	105.11
Deferred Revenue	0	0	0	0	0	2.43
Current Debt	0	109.57	0	0	0	0
Other Current Liabilities	1.35	3.53	64.38	8.04	8.04	6.66
Total Current Liabilities	90.85	230.08	168.16	179.08	162.01	114.21
Long-Term Debt	223.86	223.1	539.78	560.58	532.08	371.25
Other Long-Term Liabilities	6.62	7.45	3.04	7.68	9.25	4.58
Total Long-Term Liabilities	230.47	230.56	542.82	568.27	541.33	375.83
Total Liabilities	321.32	460.63	710.99	747.34	703.33	490.04
Total Debt	223.86	332.67	539.78	560.58	532.08	371.25
Debt Growth	-32.64%	-38.37%	-3.71%	5.36%	43.32%	4.38%
Common Stock	2,257	2,238	2,309	2,234	2,176	1,800
Retained Earnings	-2,178	-2,137	-2,490	-2,398	-2,123	-1,779
Comprehensive Income	-7.2	-8.26	-2.87	-2.48	-1.14	-2.26
Shareholders' Equity	71.85	93.08	-183.96	-166.85	51.56	19.13
Net Cash / Debt	99.78	158.24	-111.97	-83.41	125.27	64.91
Net Cash / Debt Growth	-39.72%	-	-	-	92.99%	9.57%
Net Cash Per Share	2.39	4.68	-3.51	-2.53	3.96	2.28
Working Capital	292.6	310.05	339.86	366.67	559.31	368.22
Book Value Per Share	1.72	2.75	-5.77	-5.06	1.63	0.67

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).